Using the power of proteomics to predict immunotherapy responses in melanoma and beyond
Source: Labiotech, September 2022
Next-generation proteomics has a vital role to play in the search for new biomarkers of immunotherapy response. Recent studies in melanoma presented at the European Society for Medical Oncology (ESMO) Congress highlight how these insights have the potential to transform cancer care.
The recent success of immunotherapies that manipulate the patient’s immune system to recognize and destroy cancer cells has been a game-changer in oncology. Leading the pack are inhibitors of the PD-1/PD-L1 axis, with other targets such as CTLA4 also rising to prominence.
But while these treatments have been transformational for some patients and diseases, most notably for lung cancer and melanoma they do not work for all. Currently, up to one in five patients achieves lasting results from immunotherapy and there can be significant side effects from the treatment.